Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
HF Sinclair (DINO) Eyes $100 After Surging +100% Year-to-Date

HF Sinclair (DINO) Eyes $100 After Surging +100% Year-to-Date

Key Takeaways

  • Price target in focus: $100 per share — a psychologically significant round-number level that HF Sinclair has never traded above, with its 52-week high standing at $94.22.
  • Strongest bullish factors: A recent Q2 2026 earnings beat, multiple analyst price-target upgrades from major firms including Goldman Sachs ($114) and TD Cowen ($100), and a favorable refining macro environment.
  • Key risks: The stock has already surged roughly 100% year-to-date, trailing P/E has expanded above its historical median, and several analysts maintain Hold ratings with targets below the current price.
  • Critical levels: Immediate resistance sits near the 52-week high of $94.22; a decisive breakout above that zone would clear the path toward the $100 psychological barrier.
  • Bottom line: Reaching $100 is achievable but not guaranteed — it likely requires sustained refining margins, continued execution on cost-saving initiatives, and broader energy-sector strength.

Why the $100 Level Matters

The $100 price level carries substantial psychological weight in equity markets. For HF Sinclair Corporation (DINO), an independent energy company that owns and operates seven refineries across the United States, crossing into triple-digit territory would represent uncharted ground. The stock has never closed above $94.22, its 52-week high, and has rallied roughly 100% year-to-date from around $45 at the start of 2026 to approximately $91.47 as of the most recent close. With the shares now hovering less than 10% below $100, the question of whether DINO can breach this milestone has become one of the most actively discussed topics among energy-sector investors.

Company Overview: A Diversified Refining Powerhouse

HF Sinclair Corporation operates across five business segments: Refining, Renewables, Marketing, Lubricants & Specialties, and Midstream. The company's seven refineries across Kansas, Oklahoma, New Mexico, Wyoming, Washington, and Utah provide approximately 678,000 barrels per day of crude oil throughput capacity. It also produces up to 380 million gallons of renewable diesel annually and operates roughly 4,500 miles of petroleum product pipelines. This diversified footprint — spanning traditional refining, renewables, specialty lubricants, and midstream logistics — provides multiple revenue streams that help cushion the inherent cyclicality of the refining business.

What Could Drive DINO Toward $100

Several catalysts support the case for $100. First, HF Sinclair reported a Q2 2026 earnings beat that prompted immediate analyst reactions. Goldman Sachs raised its price target to $114 from $109, maintaining a Buy rating. TD Cowen lifted its target to $100, while UBS moved to $105. These upward revisions reflect growing confidence in the company's near-term earnings power. I also checked this using Tickeron’s AI Trend Prediction Engine to see how momentum compared with peers.

The macro backdrop for refining remains constructive. Favorable crude oil differentials — particularly the Western Canadian Select (WCS) discount relative to WTI — benefit Mid-Continent refiners like HF Sinclair by lowering feedstock costs while product prices remain supported by healthy demand. Additionally, the company's estimated $400 million to $600 million in annual sustainable returns and expense (SRE) benefits offers a meaningful margin tailwind as these initiatives are realized over time.

Shareholder returns add another dimension. With a dividend yield of approximately 2.30% and a history of 38 consecutive years of dividend payments, DINO offers income-oriented investors a compelling reason to hold the stock through volatility. The company's forward P/E of roughly 7.12 also suggests the valuation is not stretched relative to expected earnings, despite the year's strong rally.

What Could Hold the Stock Back

The primary obstacle is the magnitude of the rally that has already occurred. A stock that doubles in roughly seven months can become vulnerable to profit-taking, particularly if refining margins compress or broader market conditions deteriorate. The trailing P/E ratio of approximately 8.72, while not extreme, sits above the company's five-year median, suggesting some valuation expansion has already been priced in.

Analyst sentiment, while broadly constructive, is not uniformly bullish. Of 16 analysts covering the stock, seven rate it Hold and two now rate it Sell or Strong Sell. The average 12-month price target of roughly $88.93 actually implies a modest decline from current levels. Notably, Wells Fargo maintains a Hold-equivalent rating with a target of $67, and Freedom Capital Markets initiated coverage with a Hold at $62, signaling that some analysts see the stock as fully valued or overvalued after its powerful run.

Additionally, the refining industry faces structural risks from the energy transition, including the long-term adoption of electric vehicles and renewable fuels that could dampen gasoline and diesel demand. Near-term risks include potential economic slowdowns reducing fuel consumption and regulatory changes affecting refining operations or renewable fuel mandates.

Technical Levels That Matter

From a technical perspective, DINO's chart presents a clear sequence of levels. The stock recently traded as high as $94.22, which now serves as the most immediate resistance zone. A sustained breakout above that level — ideally on above-average volume — would clear the most significant obstacle between the current price and $100. On the downside, the $84–$86 range represents a first area of support, with stronger structural support near $78–$80, where buyers previously stepped in. The stock's beta of 0.71 indicates lower volatility than the broader market, which can make breakouts more gradual but also more durable when they occur.

Analyst Opinions and Price Targets

The analyst landscape for DINO offers a wide range of perspectives. The most bullish voices include Goldman Sachs at $114 and UBS at $105, both with Buy ratings. TD Cowen's recent target of $100 places the firm in the camp that sees $100 as achievable. BMO Capital raised its target to $85 with a Buy rating, while J.P. Morgan moved to $94 with a Hold. On the more cautious side, Barclays maintains a target of $86, and Wells Fargo's $67 target represents the lower end of Street estimates. This dispersion — from $67 to $114 — reflects genuine uncertainty about the trajectory of refining margins and the durability of DINO's recent earnings strength.

Using AI Daily Buy/Sell Signals

One tool I turn to when monitoring names like DINO is AI Daily Buy/Sell Signals from Tickeron. The platform applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical patterns and market conditions. It helps me stay disciplined without spending hours reviewing charts each day.

Final Assessment

The $100 target for HF Sinclair stock is ambitious but within the realm of realistic possibility. The company's diversified refining and midstream operations, combined with favorable crude differentials, ongoing cost-efficiency programs, and strong shareholder returns, provide a solid foundation for further upside. Recent analyst upgrades — including Goldman Sachs' $114 target and TD Cowen's $100 target — indicate that respected voices on Wall Street see a path to triple digits. However, the stock's dramatic year-to-date rally, mixed analyst consensus, and elevated valuation relative to historical norms argue against taking $100 for granted. A breakout above the $94.22 resistance level would be the clearest technical signal that the $100 milestone is within reach. Investors should monitor refining margin trends, crude oil price spreads, upcoming quarterly results, and analyst rating changes to gauge whether the fundamental case for $100 continues to strengthen.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DINO

DINO in upward trend: 10-day moving average crossed above 50-day moving average on July 06, 2026

The 10-day moving average for DINO crossed bullishly above the 50-day moving average on July 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DINO advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

DINO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 280 cases where DINO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DINO moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DINO as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DINO turned negative on August 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DINO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 48, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (43.163). P/E Ratio (7.905) is within average values for comparable stocks, (18.404). Projected Growth (PEG Ratio) (1.032) is also within normal values, averaging (1.948). Dividend Yield (0.024) settles around the average of (0.057) among similar stocks. P/S Ratio (0.484) is also within normal values, averaging (0.474).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DINO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Valero Energy Corp (NYSE:VLO), MARATHON PETROLEUM Corp (NYSE:MPC), Phillips 66 (NYSE:PSX).

Industry description

The Oil Refining/Marketing segment includes companies that refine crude oil into a number of petroleum products, including gasoline, jet fuel and diesel, and then sell the usable products to the end users. These companies are involved in what’s called downstream operations in the oil business. They also engage in the marketing and distribution of crude oil and natural gas products. In other words, the downstream oil and gas business is focused on post-production processes of crude oil and natural gas. When oil prices slump, downstream businesses are hurt less or in some cases even benefit, since their purchase cost of crude oil goes down. Some of the biggest U.S. oil refining/marketing companies include Phillips 66, Marathon Petroleum Corporation and Valero Energy Corp.

Market Cap

The average market capitalization across the Oil Refining/Marketing Industry is 16.87B. The market cap for tickers in the group ranges from 107.69K to 87.07B. VLO holds the highest valuation in this group at 87.07B. The lowest valued company is AMCF at 107.69K.

High and low price notable news

The average weekly price growth across all stocks in the Oil Refining/Marketing Industry was -8%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 21%. CAPL experienced the highest price growth at 2%, while PARR experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Oil Refining/Marketing Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 65
Price Growth Rating: 41
SMR Rating: 59
Profit Risk Rating: 48
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
DINO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry OilRefiningMarketing

Profile
Details
Industry
N/A
Address
2828 North Harwood
Phone
+1 214 871-3555
Employees
5218
Web
https://www.hfsinclair.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.